BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Announces Clinical Trial of Jellyfish Sting Prevention Sunscreen on Man-O-War

Jupiter Wellness (NASDAQ: JUPW), a wellness company focused on hair, skin, and sexual wellness, has launched a clinical trial designed to explore the effectiveness of an improved formulation of NoStingz jellyfish sting prevention sunscreen against man-o-war jellyfish. The trial, which will be led by Dr. Patric Rice and Dr. Eric Stroud, will be conducted by Angelshark Consulting; the trial will take place in the Florida Keys. The company called the launch of the trial a “milestone” and noted that the trial will be focused on evaluating the human response to stings from man-o-war jellyfish when protective sunscreen developed by Jupiter is applied.

“We are thrilled to launch this clinical trial and take a major step forward in providing our customers with a dependable sunscreen solution that can protect them from man-o-war jellyfish stings,” said Jupiter Wellness CEO Brian John in the press release. “We have already seen great results from our product, and we have the data and user testimonials to back it up. This trial is specifically targeting the man-o-war jellies, which are known to have some of the most painful stings in our waters. The data generated from this trial will be invaluable in helping us develop more effective and safer sunscreen products.”

To view the full press release, visit https://ibn.fm/eD1j4

About Jupiter Wellness Inc.

Jupiter Wellness is a diversified company that supports health and wellness by researching and developing over-the-counter (“OTC”) products and intellectual property. The company’s product pipeline addresses a range of conditions, including hair loss, eczema, burns and sexual wellness. Revenue is generated through the sales of OTC and consumer products, contract research agreements and licensing royalties. For additional information about this company, please visit www.JupiterWellnessInc.com.

NOTE TO INVESTORS: The latest news and updates relating to JUPW are available in the company’s newsroom at https://ibn.fm/JUPW

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.